Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2005
11/01/2005US6960578 Glutamate receptor antagonists
11/01/2005US6960575 Thiazine derivatives
11/01/2005US6960558 Method of screening for anti-obesity agents using ciliary neutrophic factor receptor
11/01/2005US6960444 Transcriptional mediators of blood vessel development and endothelial differentiation
11/01/2005US6960440 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
11/01/2005US6960343 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
11/01/2005CA2115792C Method for the treatment of pain
10/2005
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100563A1 Follistatin mutant polypeptide
10/27/2005WO2005100562A1 OSTEOPONTIN siRNA
10/27/2005WO2005100560A1 Cell death inducer
10/27/2005WO2005099759A1 Medicine for prevention and/or treatment of arteriosclerosis
10/27/2005WO2005099736A1 Antitumor remedy
10/27/2005WO2005099735A1 Lipase inhibitor containing component of leaf of hardy rubber tree
10/27/2005WO2005099734A1 Lipase inhibitor containing water extract from leaf of hardy rubber tree
10/27/2005WO2005099696A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005WO2005099686A1 Edible composition having effects of promoting the production and release of calcitonin gene-related peptide
10/27/2005WO2005079164A3 5α-REDUCTASE INHIBITORS
10/27/2005US20050240035 polymerase inhibitors such as -1-(5-Cyano-pyridin-2-yl)-3-(1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-1-yl)-urea, used as antiviral agents
10/27/2005US20050240023 Cathepsin cysteine protease inhibitors
10/27/2005US20050240017 5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,11-dihydro-6-oxa-12-thia-dibenzo[a,f]azulen-2-ol; 13-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,13-dihydro-12-oxa-benzo[4,5]cyclohepta[1,2-a]naphthalen-3-ol or derivatives or salts; for alleviating symptoms of estrogen deprivation, including bone loss
10/27/2005US20050240009 T-cell epitopes in staphylococcal enterotoxin b
10/27/2005US20050239905 Smooth muscle peristole inhibitor
10/27/2005US20050239899 Beta-secretase inhibitors
10/27/2005US20050239896 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke, depression, glaucoma
10/27/2005US20050239884 Compositions comprising hmg-coa reductase inhibitor
10/27/2005US20050239872 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
10/27/2005US20050239860 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
10/27/2005US20050239855 For therapy of cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239834 Novel 4-diphenylmethyl piperidine derivatives
10/27/2005US20050239828 Spirocyclic amides as cannabinoid receptor modulators
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239821 Viral inhibitors
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239817 Acetic acid 6-(3,4-bis-cyclopropylmethoxy-phenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester; low toxicity; high bioavailability; large therapeutic breadth; side effects reduction; industrial scale; antiinflammatory agent, asthma, COPD, allergic rhinitis or Crohn's disease
10/27/2005US20050239815 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor
10/27/2005US20050239802 E.g., 6-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)- phenyl]cyclopent-1-enyl}-pyridine-2-carboxylic acid, used to treat prostaglandin mediated diseases that include inflammatory, neuropathic or visceral pain
10/27/2005US20050239800 Polycyclic pyrazines as potassium ion channel modulators
10/27/2005US20050239799 1-phenyl-4-benzylpiperazines dopamine receptor subtype
10/27/2005US20050239797 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity
10/27/2005US20050239786 Triazole derivatives as tachykinin receptor antagonists
10/27/2005US20050239784 3-Phenyl analogs of toxoflavine as kinase inhibitors
10/27/2005US20050239780 Tetrahydropyran derivative
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239716 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
10/27/2005US20050239711 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
10/27/2005US20050239708 Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
10/27/2005US20050239698 placental growth factor (PLGF) capable of promoting neovascularization in the treatment of diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue, scleroderma and skin ageing due to exposure to chemicals or solar radiation
10/27/2005US20050239169 Nucleotide sequences coding seladin-1polypeptide for use in treatment and prevention of alzheimer's disease
10/27/2005US20050239167 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239061 Identification and use of effectors and allosteric molecules for the alteration of gene expression
10/27/2005US20050239054 Drug screening compounds having esterified phosphonate or carboxyl groups with novel enzyme GS-7340 Ester Hydrolase and identifying the compound as a suitable prodrug by the formation of a phosphonic acid or carboxylic acid; candidate compounds
10/27/2005US20050239051 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/27/2005US20050238719 Film coating
10/27/2005US20050238643 Modulation of lir function to treat rheumatoid arthritis
10/27/2005US20050238590 Incorporation of exogenous lactic bacteria into the oral microflora
10/27/2005US20050238579 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/27/2005US20050238578 Administering anticarcinogenic agent and chelate complex of macrocyclic aminophosphonic acid and radionuclide such as samarium ethylenediaminetetramethylenephosphonic acid (EDTMP) to replace total body irradiation;antiproliferative agents; autoimmune, infectious, metabolic or genetic disorders
10/27/2005US20050236328 Chitosan-containing polysaccharide, method for preparing the same and use thereof
10/27/2005CA2562890A1 Novel g-csf conjugates
10/27/2005CA2562885A1 Follistatin variant polypeptide
10/27/2005CA2562694A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005CA2562554A1 Thio-substituted arylmethanesulfinyl derivatives
10/27/2005CA2561555A1 Bicyclic aromatic sulfinyl derivatives
10/27/2005CA2505469A1 Drug delivery device comprising a bilayered polymeric coating having a cell cycle inhibitor that acts selectively at the g1 phase of the cell cycle incorporated into the first polymer coating layer
10/26/2005EP1589115A2 Polymorphisms of the human organic anion transporting polypeptide-C (OATP-C)
10/26/2005EP1589107A1 Immunoglobulins devoid of light chains
10/26/2005EP1589100A1 Transcriptional activator
10/26/2005EP1589033A1 Antibody and use thereof
10/26/2005EP1589023A1 Oligosaccharide derivative
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1589002A1 Clausenamide c5 hydroxyl derivatives and n-substituted derivatives, processes for their preparation, its composition and use
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588726A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588718A1 Gene therapy of hepatocyte growth factor to enhance muscular and cutaneous flap survival
10/26/2005EP1588715A1 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same
10/26/2005EP1588709A1 Vitamin comprising pyroloquinoline quinone and use thereof
10/26/2005EP1588707A1 Stable solid medicinal composition for oral administration
10/26/2005EP1588703A1 Fatigue reducing agent
10/26/2005EP1588629A1 Matrix-forming composition containing pectin
10/26/2005EP1587819A2 Isolation and purification procedure of vasopeptidase peptide inhibitors
10/26/2005EP1587541A2 Compositions and methods of tolerizing a primate to an antigen
10/26/2005EP1587477A2 Odorless formulation for treating mucosal discontinuities
10/26/2005EP1501859B1 17a-FLUOROALKYL-11BETA-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS
10/26/2005EP1440071B1 Imidazopyridine compounds as 5-ht 4? receptor modulators
10/26/2005EP1397354B1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
10/26/2005EP1390368B1 Disubstituted 7,9-guaninium halides as telomerase inhibitors
10/26/2005EP1381607B1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepine-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/26/2005EP1289965B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/26/2005EP1246626B1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance
10/26/2005EP1212081B1 Use of ace inhibitors in the prevention of congestive heart failure
10/26/2005EP1185277B1 Use of FXR synthetic ligands for the treatment of diseseas linked to cholesterol imbalance and colon cancer
10/26/2005EP1183229B1 Glucagon antagonists/inverse agonists
1 ... 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 ... 1564